Clinical studies with agents active on the 5‐lipoxygenase pathway
- 1 January 1995
- Vol. 50 (s22) , 22-26
- https://doi.org/10.1111/j.1398-9995.1995.tb02731.x
Abstract
Leukotrienes may be considered asthmatic mediators. Compounds inhibiting their production and activity show promise in the treatment of asthma. Further clinical studies will determine the clinical usefulness of such agents.Keywords
This publication has 37 references indexed in Scilit:
- Mediator and cytokine mechanisms in asthma.Thorax, 1993
- AsthmaNew England Journal of Medicine, 1992
- Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthmaJournal of Allergy and Clinical Immunology, 1992
- Leukotriene (LT) D4Is Involved in Antigen-Induced Asthma: a Study with the LTD4Receptor Antagonist, MK-571Annals of the New York Academy of Sciences, 1991
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.Thorax, 1991
- Effect of the oral leukotriene D antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D in atopic subjectsJournal of Allergy and Clinical Immunology, 1989
- URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITISThe Lancet, 1989
- Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological EffectsScience, 1987
- In vivo metabolism of leukotriene C4 in man: Urinary excretion of leukotriene E4Biochemical and Biophysical Research Communications, 1985